These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 25888743)

  • 21. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.
    Tan Q; Zhu Y; Li J; Chen Z; Han GW; Kufareva I; Li T; Ma L; Fenalti G; Li J; Zhang W; Xie X; Yang H; Jiang H; Cherezov V; Liu H; Stevens RC; Zhao Q; Wu B
    Science; 2013 Sep; 341(6152):1387-90. PubMed ID: 24030490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.
    Espirito-Santo M; Santos-Costa Q; Calado M; Dorr P; Azevedo-Pereira JM
    AIDS Res Hum Retroviruses; 2012 May; 28(5):478-85. PubMed ID: 21902586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.
    Maeda Y; Takemura T; Chikata T; Kuwata T; Terasawa H; Fujimoto R; Kuse N; Akahoshi T; Murakoshi H; Tran GV; Zhang Y; Pham CH; Pham AHQ; Monde K; Sawa T; Matsushita S; Nguyen TV; Nguyen KV; Hasebe F; Yamashiro T; Takiguchi M
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32295903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peptide ligands selected with CD4-induced epitopes on native dualtropic HIV-1 envelope proteins mimic extracellular coreceptor domains and bind to HIV-1 gp120 independently of coreceptor usage.
    Dervillez X; Klaukien V; Dürr R; Koch J; Kreutz A; Haarmann T; Stoll M; Lee D; Carlomagno T; Schnierle B; Möbius K; Königs C; Griesinger C; Dietrich U
    J Virol; 2010 Oct; 84(19):10131-8. PubMed ID: 20660187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Envelope-dependent restriction of human immunodeficiency virus type 1 spreading in CD4(+) T lymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation.
    Vicenzi E; Bordignon PP; Biswas P; Brambilla A; Bovolenta C; Cota M; Sinigaglia F; Poli G
    J Virol; 1999 Sep; 73(9):7515-23. PubMed ID: 10438841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRF01_AE and CRF02_AG [corrected].
    Mulinge M; Lemaire M; Servais JY; Rybicki A; Struck D; da Silva ES; Verhofstede C; Lie Y; Seguin-Devaux C; Schmit JC; Bercoff DP
    PLoS One; 2013; 8(5):e60566. PubMed ID: 23667426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
    Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.
    Ghaffari G; Tuttle DL; Briggs D; Burkhardt BR; Bhatt D; Andiman WA; Sleasman JW; Goodenow MM
    J Virol; 2005 Nov; 79(21):13250-61. PubMed ID: 16227248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
    Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
    Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.
    Nolan KM; Del Prete GQ; Jordan AP; Haggarty B; Romano J; Leslie GJ; Hoxie JA
    J Virol; 2009 Apr; 83(8):3798-809. PubMed ID: 19193800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
    Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
    Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
    Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
    Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion.
    Mulampaka SN; Dixit NM
    PLoS One; 2011; 6(5):e19941. PubMed ID: 21647388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of CD4 and coreceptors in binding, endocytosis, and proteolysis of gp120 envelope glycoproteins derived from human immunodeficiency virus type 1.
    Kozak SL; Kuhmann SE; Platt EJ; Kabat D
    J Biol Chem; 1999 Aug; 274(33):23499-507. PubMed ID: 10438529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
    Blanco J; Barretina J; Clotet B; Esté JA
    J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
    Kang Y; Wu Z; Lau TC; Lu X; Liu L; Cheung AK; Tan Z; Ng J; Liang J; Wang H; Li S; Zheng B; Li B; Chen L; Chen Z
    J Biol Chem; 2012 May; 287(20):16499-509. PubMed ID: 22447925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains.
    Alfano M; Schmidtmayerova H; Amella CA; Pushkarsky T; Bukrinsky M
    J Exp Med; 1999 Sep; 190(5):597-605. PubMed ID: 10477545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
    Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
    Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests.
    Miyake H; Iizawa Y; Baba M
    J Clin Microbiol; 2003 Jun; 41(6):2515-21. PubMed ID: 12791875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
    Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
    J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.